Scarica l'app Stockscreener
4.665
0.32%
0.015
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.65
Aprire:
$4.57
Volume 24 ore:
102.32K
Relative Volume:
2.39
Capitalizzazione di mercato:
$4.46M
Reddito:
$61,000
Utile/perdita netta:
$-5.46M
Rapporto P/E:
-0.7133
EPS:
-6.54
Flusso di cassa netto:
$-6.76M
1 W Prestazione:
-4.41%
1M Prestazione:
-8.35%
6M Prestazione:
+28.16%
1 anno Prestazione:
-32.27%
Intervallo 1D:
$4.3942
$4.92
Intervallo di 1 settimana:
$4.16
$5.12
Portata 52W:
$3.03
$14.80
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Nome
Titan Pharmaceuticals Inc De
Settore
Industria
Telefono
(650) 244-4990
Indirizzo
400 OYSTER POINT BLVD, SAN FRANCISCO
Confronta TTNP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
4.8753 | 4.46M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.24 | 114.39B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
505.21 | 52.99B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.26 | 39.91B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
584.30 | 35.70B | 2.58B | 1.06B | -1.28B | 16.33 |
|
BNTX
Biontech Se Adr
|
108.16 | 27.19B | 2.97B | -812.83M | -1.24B | -3.3962 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-06-26 | Iniziato | Maxim Group | Buy |
| 2017-11-10 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Borsa (TTNP) Ultime notizie
Titan Medical (NASDAQ:TMDIF) Stock Price Down 2.4% – Here’s Why - Defense World
Merger Alert: Titan Pharmaceuticals Takes Major Step Toward TalenTec Combination with Critical SEC Filing - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
Biotech Rising Star Conduit Pharmaceuticals Gets Green Light for Nasdaq Capital Market Transfer - Stock Titan
Petros Pharmaceuticals Faces NASDAQ Delisting Despite $10M Cash Position, Plans Appeal - Stock Titan
Conduit Pharmaceuticals Secures Future on Nasdaq: Clears Both Bid Price and Equity Hurdles - Stock Titan
Conduit Pharma Sets 15:1 Reverse Split: Shares Drop to 755,900 Starting May 20 - Stock Titan
Biotech Company Makes Bold Leap into AI: Bionoid Pharma Rebrands as AI Maverick Intel - Stock Titan
HOPE Therapeutics Lands $7.8M Deal to Build National Mental Health Network with Ketamine Treatment Centers - Stock Titan
Regeneron Secures Massive $407M Victory: Jury Finds Amgen Guilty of Illegal PCSK9 Drug Bundling Scheme - Stock Titan
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - Stock Titan
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Stock Titan
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - Stock Titan
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT | CYCC Stock News - Stock Titan
NRXP Reveals Major Mental Health Expansion Plans at Exclusive Mar-A-Lago Investor Event - Stock Titan
Citius Pharmaceuticals Reveals Growth Strategy at Major Jefferies Healthcare Conference - Stock Titan
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
Generic Percocet Launch: Elite Pharmaceuticals Targets $317M Pain Management Market - Stock Titan
Trump Executive Order Validates Petros' AI Technology Platform for Revolutionary Drug Access Reform - Stock Titan
Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan
Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan
X4 Pharmaceuticals Strengthens Team with 450,000 Share Options Grant: Inside the Retention Plan - Stock Titan
Major UK Retail Breakthrough: Sonoma's Natural Acne Treatment to Roll Out Across 1,200 Leading Pharmacies - Stock Titan
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
Vincerx Pharma Announces Complete Liquidation and Nasdaq Exit: What Happens to Your Shares? - Stock Titan
Strategic Win: Phathom Taps 30-Year Pharma Veteran to Drive VOQUEZNA Commercial Success - Stock Titan
US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga
Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan
Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan
Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan
Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan
Dogwood Therapeutics Saves Nasdaq Status: $17.5M Cash, Zero Debt After Major Financial Overhaul - Stock Titan
Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan
Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Petros Pharmaceuticals Targets $38B Self-Care Market with Game-Changing AI Drug Platform - Stock Titan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
NRx Pharmaceuticals Slashes Losses by 33% While Securing $300M+ Potential Deal - Stock Titan
Titan Pharmaceuticals Inc De Azioni (TTNP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.47%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):